Nanoscale ZIF-8 as an efficient carboplatin carrier for targeted cancer therapy

Cancer is a leading cause of death worldwide and is becoming more prevalent. Carboplatin (CBP) is an anti-cancer medication from the platinum group of substances that are frequently employed in chemotherapy, and it is an active anti-cancer agent. However, the adverse effects of platinum medications, including its lack of selectivity, significant systemic toxicity, and drug resistance, limit its usage. The zeolitic imidazolate framework-8 (ZIF-8) has gained global biomedical interest for its high drug loading capacity and controlled release into target cells. It is synthesized using a non-solvothermal method and has shown the capacity to regulate and enhance the selectivity of cancer cells. A rapid high-performance liquid chromatography equipped with photodiode array detector (HPLC-PDA) method was used to measure the CBP loading capacity on ZIF-8, and the result was found to be 0.066 mg mg−1. ZIF-8 could effectively protect CBP in the in vitro release test in the physiological environment (pH 7.4). When pH 5.5 was reached, ZIF-8 served as a pH-resposive nanocarrier, leading to gradual CPB release. Studies on the in vitro cytotoxicity of CBP showed that the IC50 of CBP for the lung cancer cell line was significantly lowered upon encapsulation of CBP in nanoparticles.